SynAffix is a life sciences company based in Nijmegen, The Netherlands. SynAffix’ proprietary site-specific bioconjugation platform involves the (post-recombinant) introduction of a specific tag into a protein of interest, to enable the smooth and irreversible attachment of a functionality of interest through a metal-free click reaction.
A particular opportunity of this approach lies in the development of next generation antibody-drug conjugates (ADCs), with full control of stability, site-specificity and drug-antibody ratio. Other technology applications comprise tailoring of protein properties involves the selective chemical modification with specific molecular entities such as PEG chains, fluorophores, radionuclides, nano particles and so on.
SynAffix is currently establishing its own proprietary biopharmaceuticals pipeline in the field of targeted cancer therapies and is actively pursuing licensing opportunities and co-development collaborations.